NSCLC patients with ALK/ROS1 rearrangements are more likely to develop thrombosis than patients with other oncogenic alterations. Thrombosis may also be associated with an inferior response and PFS after TKI therapy. READ ARTICLE.
Translational Lung Cancer Research DOI: 10.21037/tlcr-20-1290
Authors: Yiwei Liu, Wanying Wang, Fengying Wu, Guanghui Gao, Jian Xu, Xuefei Li, Chao Zhao, Shuo Yang, Shiqi Mao, Yingying Pan, Keyi Jia, Chuchu Shao, Bin Chen, Shengxiang Ren, Caicun Zhou